Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Scott Miller

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
The Lancet. Oncology|April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Cancer|February 11, 2004
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesPaul J Hesketh, Francis Arena, Dhimant Patel, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
The Lancet. Oncology|April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Cancer|February 11, 2004
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesPaul J Hesketh, Francis Arena, Dhimant Patel, et al.
Pageof 4